“Personalizing treatment in this way may lessen harmful side effects, reduce damage to healthy cells and make it more likely ...

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

An expert discusses how CT scans and bone scans remain the standard imaging approach for most patients with metastatic ...

Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, as of July 2, 2025, Pluvicto® (lutetium (177Lu) vipivotide tetraxetan injection) is publicly reimbursed in Quebec for ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

The FDA granted fast track designation to TRE-515 plus radioligand therapy for treating PSMA-positive metastatic castration-resistant prostate cancer.

Bristol Myers Squibb has opened its radiopharmaceutical manufacturing facility in Indianapolis, which played a major role in ...

Take a closer look at the radiopharma new wave as Nuclidium and Actithera raise big to develop their platforms.

The data indicated that the leading drug demonstrated superior cancer cell killing in contrast to Xtandi (enzalutamide) and ...

The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.